{"id":"epirubicin-paclitaxel-filgrastim","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin intercalates into DNA and generates reactive oxygen species to kill rapidly dividing cancer cells. Paclitaxel stabilizes microtubules and prevents cell division. Filgrastim (G-CSF) stimulates neutrophil production to mitigate chemotherapy-induced neutropenia. Together, this combination targets breast cancer cells through complementary cytotoxic mechanisms while managing treatment-related myelosuppression.","oneSentence":"This combination regimen uses an anthracycline chemotherapy agent and a taxane to damage cancer cell DNA and disrupt microtubule formation, supported by a growth factor to maintain bone marrow function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:27.313Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely early-stage or locally advanced, given Phase 3 context and gynaecological oncology focus)"}]},"trialDetails":[{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT03498716","phase":"PHASE3","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-02","conditions":"Triple Negative Breast Cancer","enrollment":2199},{"nctId":"NCT00014222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-12-04","conditions":"Breast Cancer","enrollment":2104},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00003852","phase":"PHASE2","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors","status":"TERMINATED","sponsor":"UNICANCER","startDate":"1998-03","conditions":"Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer","enrollment":45},{"nctId":"NCT02225652","phase":"PHASE2","title":"A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2010-09","conditions":"Women With Primary Breast Cancer","enrollment":11},{"nctId":"NCT00011921","phase":"PHASE3","title":"Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"EBMT Solid Tumors Working Party","startDate":"1997-09","conditions":"Lung Cancer","enrollment":430},{"nctId":"NCT00072319","phase":"PHASE2","title":"Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-08","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01378533","phase":"PHASE3","title":"The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-05","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT00668616","phase":"PHASE3","title":"Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes","status":"COMPLETED","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2000-03","conditions":"Breast Cancer","enrollment":1034},{"nctId":"NCT00431080","phase":"PHASE3","title":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-08","conditions":"Breast Cancer","enrollment":478}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epirubicin, Paclitaxel, Filgrastim","genericName":"Epirubicin, Paclitaxel, Filgrastim","companyName":"North Eastern German Society of Gynaecological Oncology","companyId":"north-eastern-german-society-of-gynaecological-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses an anthracycline chemotherapy agent and a taxane to damage cancer cell DNA and disrupt microtubule formation, supported by a growth factor to maintain bone marrow function. Used for Breast cancer (likely early-stage or locally advanced, given Phase 3 context and gynaecological oncology focus).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}